iA Global Asset Management Inc. Grows Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

iA Global Asset Management Inc. grew its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 3.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 133,474 shares of the medical research company's stock after acquiring an additional 4,393 shares during the period. Thermo Fisher Scientific comprises 1.2% of iA Global Asset Management Inc.'s portfolio, making the stock its 17th largest holding. iA Global Asset Management Inc.'s holdings in Thermo Fisher Scientific were worth $69,437,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its holdings in Thermo Fisher Scientific by 1.7% during the third quarter. Geode Capital Management LLC now owns 7,659,943 shares of the medical research company's stock worth $4,719,477,000 after buying an additional 127,564 shares in the last quarter. Coldstream Capital Management Inc. boosted its stake in shares of Thermo Fisher Scientific by 11.4% during the 3rd quarter. Coldstream Capital Management Inc. now owns 9,705 shares of the medical research company's stock worth $5,972,000 after acquiring an additional 995 shares in the last quarter. Greenwood Gearhart Inc. increased its stake in Thermo Fisher Scientific by 9.8% in the 3rd quarter. Greenwood Gearhart Inc. now owns 20,579 shares of the medical research company's stock valued at $12,730,000 after purchasing an additional 1,837 shares in the last quarter. Nordea Investment Management AB raised its holdings in Thermo Fisher Scientific by 23.6% during the fourth quarter. Nordea Investment Management AB now owns 55,452 shares of the medical research company's stock worth $28,868,000 after purchasing an additional 10,606 shares during the last quarter. Finally, S.E.E.D. Planning Group LLC boosted its position in Thermo Fisher Scientific by 6.2% during the fourth quarter. S.E.E.D. Planning Group LLC now owns 10,626 shares of the medical research company's stock worth $5,528,000 after purchasing an additional 618 shares in the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Insider Buying and Selling

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the company's stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $175,677.00. Following the completion of the transaction, the executive vice president now owns 16,363 shares in the company, valued at $9,582,009.17. This represents a 1.80 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Michael A. Boxer sold 3,775 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the sale, the senior vice president now owns 10,816 shares in the company, valued at $5,759,736.32. This represents a 25.87 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 23,900 shares of company stock valued at $13,106,062. Company insiders own 0.34% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on TMO. StockNews.com raised Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research note on Tuesday, January 14th. Sanford C. Bernstein upgraded shares of Thermo Fisher Scientific from a "market perform" rating to an "outperform" rating and set a $630.00 target price for the company in a research report on Friday, January 10th. UBS Group raised their price objective on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a "buy" rating in a research note on Friday, January 31st. Scotiabank upped their target price on Thermo Fisher Scientific from $605.00 to $650.00 and gave the company a "sector perform" rating in a research note on Monday, February 3rd. Finally, Morgan Stanley raised their price target on Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an "overweight" rating in a research report on Friday, January 31st. Four research analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $653.23.

Thermo Fisher Scientific Trading Up 0.5 %

Shares of TMO stock traded up $2.53 on Monday, reaching $520.25. 1,099,952 shares of the stock were exchanged, compared to its average volume of 1,538,823. Thermo Fisher Scientific Inc. has a 1-year low of $493.30 and a 1-year high of $627.88. The stock has a market cap of $196.27 billion, a P/E ratio of 31.47, a price-to-earnings-growth ratio of 2.99 and a beta of 0.79. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. The firm has a 50 day moving average of $545.44 and a two-hundred day moving average of $554.91.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, topping analysts' consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.33%. The ex-dividend date is Friday, March 14th. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.39. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 10.41%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.